A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura
NCT ID: NCT04683003
Last Updated: 2025-04-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
77 participants
INTERVENTIONAL
2021-04-14
2027-03-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
TTP is caused by a lack of activity in the ADAMTS13 enzyme, a protein in the blood involved in controlling clotting of the blood. The ADAMTS13 enzyme breaks up another blood protein called von Willebrand factor that forms blood clots by clumping together with platelets. Some people are born with this condition, while others develop the condition during their life. Many people who are born with TTP experience frequent flare-ups that need to be treated right away. TAK-755 is a medicine that replaces ADAMTS13 and may prevent or control TTP flare-ups, called acute TTP events.
The main aim of the study is to check for side effects of long-term treatment with TAK-755. Treatment will be given in 2 ways:
1. TAK-755 treatment given either every week or every other week to prevent acute TTP events from happening (the "prophylactic" cohort).
2. TAK-755 treatment given to control an acute TTP event when it happens (the "on-demand" cohort).
Participants in the prophylactic cohort will receive treatment in the clinic or at home for up to approximately 3 years. They will visit the clinic at least every 12 weeks. Participants in the on-demand cohort will receive daily treatment for the acute TTP event until the flare-up has gotten better. They will have a follow-up visit at the clinic 4 weeks later.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP)
NCT03393975
A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)
NCT05714969
Expanded Access Program of TAK-755 for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
NCT05770219
Low Dose Rituximab in Thrombotic Thrombocytopenic Purpura
NCT01554514
Phase 1 Dose Escalation, Single Dose Study to Assess Safety and Pharmacokinetics of BAX930 in Hereditary Thrombotic Thrombocytopenic Purpura (TTP)
NCT02216084
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
TAK-755 is given slowly through a vein (intravenous infusion). Participants in the prophylactic cohort will be able to opt for treatment in a home setting by caregiver or self-infusion subject to conditions and to local regulatory approval.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Prophylactic Cohort: TAK-755
All participants will receive prophylactic treatment with 40 IU/kg TAK-755 intravenous (IV) infusions once every week or once every other week for the duration of the study.
Participants who are naïve will receive an initial IV dose of 40 IU/kg TAK-755 to allow measurement of the pharmacokinetics of TAK-755, followed by prophylactic treatment with 40 IU/kg TAK-755 by IV infusion once every week or once every other week for the duration of the study.
TAK-755
TAK-755 IV infusion
On-Demand Cohort: TAK-755
Participants will receive daily IV infusions of TAK-755 when experiencing an acute thrombotic thrombocytopenic purpura (TTP) event until 2 days after the acute TTP event is resolved.
Participants will receive 40 IU/kg TAK-755 on the first day, followed by 20 IU/kg on Day 2, and then 15 IU/kg daily until 2 days after the acute TTP event has resolved. Upon resolution of the acute TTP event, participants may choose to move to the prophylactic cohort of the study or discontinue entirely from the study.
TAK-755
TAK-755 IV infusion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
TAK-755
TAK-755 IV infusion
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants or legally authorized representative has provided signed informed consent \>=18 years of age and/or assent form \<18 years of age.
* Participant 0 to 70 years of age at the time of screening of the 281102 (NCT03393975) study.
* Participant has been diagnosed with severe congenital ADAMTS-13 deficiency.
* Participant does not display any severe thrombotic thrombocytopenic purpura (TTP) signs (platelet count \<100,000/ microliter (mcL) and elevation of lactate dehydrogenase (LDH) greater than (\>) 2 × ULN at screening (prophylactic cohort only).
* Participants \>=16 years of age must have a Karnofsky score \>= 70% and participants \<16 years of age must have a Lansky score \>=80%.
* If female of childbearing potential, participant presents with a negative serum or urine pregnancy test confirmed not more than 7 days before the first IP administration and agrees to employ adequate birth control measures for the duration of the study and to undergo quarterly pregnancy testing.
* Sexually active males must use an accepted and effective method of contraception during the treatment and until a minimum of 16 days after the last dose administered.
* Participant is willing and able to comply with the requirements of the protocol.
All naïve participants and non-naïve on-demand cohort participants:
Naïve participants can only be enrolled in this continuation after enrollment of the adult participants in the prophylactic arm of TAK-755 Phase 3 pivotal study 281102 (NCT03393975) has been completed. Naïve pediatric participants can be enrolled after enrollment of the respective age cohort into the pivotal Phase 3 study 281102 (NCT03393975) has been completed. The following criteria also applies to participants who completed study 281101 (NCT02216084), but did not participate in 281102 (NCT03393975).
Naïve participants and participants who were enrolled into the on-demand cohort of theTAK-755 Phase 3 pivotal study 281102 (NCT03393975) who meet ALL of the following criteria are eligible for this study:
* Participant is naïve or was enrolled into the on-demand cohort of the TAK-755 Phase 3 pivotal study 281102 (NCT03393975) for treatment of an acute TTP event but did not receive prophylactic treatment.
* Participant or legally authorized representative has provided signed informed consent (\>=18 years of age) and/or assent form (\<18 years of age).
* Participant is 0 to 70 years of age at the time of screening.
* Participant has been diagnosed with severe congenital ADAMTS-13 deficiency defined as:
* Confirmed by molecular genetic testing, documented in participant history or at screening, and
* ADAMTS-13 activity \<10% as measured by the fluorescence resonance energy transfer (FRETS)-VWF73 assay, documented in participant history or at screening. Participants currently receiving standard of care prophylactic therapy may exceed 10% ADAMTS-13 activity at screening.
* Participants currently receiving prophylactic therapy will be screened immediately prior to their usual prophylactic infusion.
* Participant does not display any severe TTP signs (platelet count \<100,000/microliter (mcL) and elevation of LDH \>2 × ULN) at screening (prophylactic cohort only).
* Participants \>=16 years of age must have a Karnofsky score \>=70% and participants \<16 years of age must have a Lansky score \>=80%.
* Participants is hepatitis C virus negative (HCV-) as confirmed by antibody or polymerase chain reaction testing OR HCV positive (HCV+) if their disease is chronic but stable.
* If female of childbearing potential, participant presents with a negative serum or urine pregnancy test confirmed not more than 7 days before the first IP administration and agrees to employ adequate birth control measures for the duration of the study and to undergo quarterly pregnancy testing.
* Sexually active males must use an accepted and effective method of contraception during treatment and until a minimum of 16 days after the last dose administered.
* Participant is willing and able to comply with the requirements of the protocol.
Participants from an Expanded Access Program or participants in Study 281102 (NCT03393975) who had an allergic reaction to standard of care prophylactic treatment must meet all of the following criteria:
Participants from an expanded access program as well as participants who participated in Study 281102(NCT03393975) who had an allergic reaction to standard-of-care prophylactic treatment are eligible for enrollment in the continuation study if they meet ALL of the following criteria.
* Participants or legally authorized representative has provided signed informed consent (\>=18 years of age) and/or assent (\<18 years of age).
* Participants is 0 to 70 years of age at the time of screening.
* Participants has been diagnosed with severe congenital ADAMTS-13 deficiency defined as:
* Confirmed by molecular genetic testing, documented in participant history or at screening, and
* ADAMTS-13 activity \<10% as measured by the fluorescence resonance energy transfer (FRETS)- VWF 73 assay, documented in participant history or at screening. Participants currently receiving standard of care prophylactic therapy may exceed 10% ADAMTS 13 activity at screening.
* Participant does not display any severe TTP signs (platelet count \<100,000/mcL and elevation of LDH \>2 × ULN) at screening (prophylactic cohort only).
* Participants \>=16 years of age must have a Karnofsky score \>=70% and participants \<16 years of age must have a Lansky score \>=80%.
* If female of childbearing potential, participant presents with a negative serum or urine pregnancy test confirmed not more than 7 days before the first IP administration and agrees to employ highly effective birth control measures for the duration of the study and to undergo quarterly pregnancy testing.
* Sexually active males must use an accepted and effective method of contraception during treatment and until a minimum of 16 days after the last dose administered.
* Participant is willing and able to comply with the requirements of the protocol.
Exclusion Criteria
* Participant has been diagnosed with any other TTP-like disorder (microangiopathic hemolytic anemia), including immune-mediated TTP.
* Known life-threatening hypersensitivity reaction, including anaphylaxis, to the parent molecule ADAMTS-13, hamster protein, or other constituents of TAK-755.
* Participant has a presence of a functional ADAMTS-13 inhibitor at screening.
* Participant has a medical history of a genetic or acquired immune deficiency that would interfere with the assessment of product immunogenicity, including participants who are human immunodeficiency virus-positive with an absolute cluster of differentiation 4 (CD4) count \< 200/ cubic millimeter (mm\^3) or who are receiving chronic immunosuppressive drugs.
* Participant has a history of significant neurological events, such as major stroke, indicating that a relapse might have severe consequences, as judged by the investigator.
* Participant has been diagnosed with severe cardiovascular disease (New York Heart Association classes 3 to 4).
* Participant with end stage renal disease requiring chronic dialysis.
* Participant has been diagnosed with hepatic dysfunction, as evidenced by, but not limited to, any of the following:
* Serum alanine aminotransferase \>= 2 × ULN
* Severe hypoalbuminemia \<24 gram per liter (g/L)
* Portal vein hypertension (e.g., presence of otherwise unexplained splenomegaly, history of esophageal varices).
* In the opinion of the investigator, the participant has another clinically significant concomitant disease that may pose additional risks for the participant.
* Participant has been treated with an immunomodulatory drug, excluding topical treatment (e.g., ointments, nasal sprays), within 30 days prior to enrollment. Use of corticosteroids in conjunction with administration of fresh frozen plasma to prevent allergic reactions is permitted.
* Participant has an acute illness (e.g., influenza, flu-like syndrome, allergic rhinitis/conjunctivitis, bronchial asthma) at the time of screening (prophylactic cohort only).
* Participant is receiving or anticipates receiving another investigational drug and/or interventional drug within 30 days before enrollment.
* Participant has a history of drug and/or alcohol abuse within the last 2 years.
* Participant has a progressive fatal disease and/or life expectancy of \<= 3 months.
* Participant is identified by the investigator as being unable or unwilling to cooperate with study procedures.
* Participant suffers from a mental condition rendering him/her unable to understand the nature, scope, and possible consequences of the study and/or evidence of an uncooperative attitude.
* Participant is a family member or employee of the sponsor or investigator.
* If female, participant is pregnant or lactating at the time of enrollment.
* In the UK only: Participants who have not previously received a dose of TAK-755.
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Takeda Development Center Americas, Inc.
INDUSTRY
Shire
INDUSTRY
Takeda
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Study Director
Role: STUDY_DIRECTOR
Takeda
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Childrens Healthcare of Atlanta
Atlanta, Georgia, United States
Roswell Park Comprehensive Cancer Center
Buffalo, New York, United States
Duke University Medical Center
Durham, North Carolina, United States
Mid Ohio Heart Clinic Inc
Dublin, Ohio, United States
University of Oklahoma
Oklahoma City, Oklahoma, United States
AKH - Medizinische Universität Wien
Vienna, , Austria
Beijing Children's Hospital
Beijing, Beijing Municipality, China
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Tongji Hospital Affiliated to Tongji Medicine University
Wuhan, Hubei, China
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsushe, China
Institute of Hematology and Hospital of Blood Disease
Tianjin, Tianjin Municipality, China
Hôpital Necker - Enfants Malades
Paris, Paris, France
CHU Saint Etienne - Hôpital Nord
Saint-Priest-en-Jarez Cedex, Pays de la Loire Region, France
Hôpital Saint-Antoine
Paris, , France
Hôpital Robert Debré- Paris
Paris, , France
Universitaetsklinikum Hamburg-Eppendorf
Hamburg, , Germany
Universitaetsklinikum Jena, Klinik fuerKinder-und Jugendmedizin
Jena, , Germany
Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII)
Bergamo, Hubei, Italy
Kyushu University Hospital
Fukuoka, Fukuoka, Japan
Hyogo College of Medicine Hospital
Nishinomiya, Hyōgo, Japan
Medical Hospital,Tokyo Medical and Dental University
Bunkyo City, Tokyo, Japan
Samodzielny Publiczny Dzieciecy Szpital Kliniczny
Warsaw, , Poland
Instytut Hematologii i Transfuzjologii
Warsaw, , Poland
Complejo Hospitalario Universitario A Coruña
A Coruña, La Coruña, Spain
Hospital de Cruces
Barakaldo, Vizcaya, Spain
Inselspital -Universitaetsspital Bern
Bern, , Switzerland
University College London Hospitals
London, Greater London, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Site contact
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
To obtain more information on the study, click here/on this link.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020-003348-10
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
TAK-755-3002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.